▁Anal 10.375
yst 4.77734375
s 2.982421875
▁await 11.4453125
▁new 7.38671875
▁evidence 10.2421875
▁about 7.14453125
▁British 10.578125
▁Bi 9.7734375
ote 5.49609375
ch 6.73828125
' 8.4921875
s 3.142578125
▁anti 7.046875
- 0.99658203125
can 9.234375
cer 3.814453125
▁treatment 7.5703125
▁Mar 9.3203125
im 7.796875
ast 9.9609375
at 5.0625
▁at 7.0390625
▁ES 11.5703125
MO 8.5
▁meeting 11.8359375
<0x0A> 4.046875
<0x0A> 5.10546875
In 5.33984375
vest 5.23046875
ors 3.326171875
▁and 2.951171875
▁ph 8.4921875
arma 0.400390625
ce 0.12237548828125
ut 0.0004696846008300781
ical 0.01197052001953125
▁anal 5.421875
yst 0.004486083984375
s 0.03631591796875
▁are 2.9375
▁eager 6.63671875
ly 1.646484375
▁await 0.58203125
ing 0.014892578125
▁new 3.599609375
▁clin 4.1484375
ical 0.00737762451171875
▁trial 1.564453125
▁data 1.1240234375
▁on 2.31640625
▁British 8.5625
▁Bi 1.2138671875
ote 0.041168212890625
ch 0.2276611328125
' 2.408203125
s 0.0213623046875
▁experimental 5.6171875
▁anti 3.904296875
- 0.08880615234375
can 0.162353515625
cer 0.0088348388671875
▁drug 1.4716796875
▁Mar 3.568359375
im 1.0361328125
ast 0.155517578125
at 0.01428985595703125
▁at 2.01953125
▁the 2.818359375
▁European 3.06640625
▁Society 0.353271484375
▁of 0.52978515625
▁Medical 0.4033203125
▁On 0.14306640625
col 0.0128326416015625
ogy 2.9921531677246094e-05
▁meeting 2.61328125
▁this 2.74609375
▁week 0.51904296875
. 0.79052734375
▁Mar 3.544921875
im 0.067626953125
ast 0.0178375244140625
at 0.00305938720703125
▁is 0.5595703125
▁an 1.94921875
▁anti 1.8984375
- 0.0305938720703125
can 0.331787109375
cer 0.004955291748046875
▁drug 0.74853515625
▁that 1.2431640625
▁works 3.7421875
▁by 0.47265625
▁in 1.689453125
hib 0.00527191162109375
iting 0.004421234130859375
▁en 4.54296875
zym 0.0108642578125
es 0.1328125
▁involved 2.23828125
▁in 0.037322998046875
▁tum 3.251953125
or 0.231689453125
▁growth 0.85546875
▁and 1.193359375
▁spread 2.2890625
. 0.65380859375
<0x0A> 1.63671875
<0x0A> 0.08099365234375
In 2.908203125
▁previous 10.5546875
▁clin 1.71484375
ical 0.0006623268127441406
▁tri 0.445556640625
als 6.818771362304688e-05
, 0.330322265625
▁Mar 0.4365234375
im 0.0015573501586914062
ast 0.002841949462890625
at 0.000911712646484375
▁has 0.91357421875
▁shown 0.85400390625
▁promise 1.3994140625
▁in 0.50927734375
▁extending 7.015625
▁surv 1.7724609375
ival 0.004039764404296875
▁and 2.08203125
▁slow 3.625
ing 0.0009398460388183594
▁tum 0.97509765625
or 0.01024627685546875
▁pro 2.4609375
gression 0.007579803466796875
▁in 0.4658203125
▁patients 0.48388671875
▁with 0.048004150390625
▁advanced 1.5322265625
▁pan 3.306640625
cre 0.00081634521484375
atic 0.01201629638671875
, 2.89453125
▁o 2.33203125
var 0.01329803466796875
ian 0.00014293193817138672
▁and 1.7509765625
▁g 3.3203125
astr 0.275146484375
ic 0.00580596923828125
▁can 0.5830078125
cers 9.179115295410156e-05
. 0.140625
▁The 1.966796875
▁new 2.3203125
▁Ph 4.0859375
ase 0.0013532638549804688
▁III 2.701171875
▁trial 1.091796875
▁results 4.4609375
▁to 6.6796875
▁be 0.0799560546875
▁presented 0.272216796875
▁this 1.416015625
▁week 0.0302581787109375
▁involve 5.9140625
▁over 5.62890625
▁ 0.03375244140625
7 2.59765625
0 0.225341796875
0 0.0302581787109375
▁patients 0.11297607421875
▁with 0.36376953125
▁advanced 0.7041015625
▁st 5.75
om 0.001190185546875
ach 0.0002071857452392578
▁cancer 0.84423828125
▁who 1.89453125
▁were 1.341796875
▁given 3.08203125
▁Mar 0.78125
im 0.0008950233459472656
ast 0.003223419189453125
at 0.00164031982421875
▁in 1.712890625
▁combination 0.434814453125
▁with 0.00946807861328125
▁standard 1.5029296875
▁chem 0.841796875
other 0.02398681640625
apy 0.0180206298828125
. 0.338623046875
▁Anal 6.24609375
yst 0.00878143310546875
s 0.0265960693359375
▁expect 2.1171875
▁the 1.22265625
▁data 2.26953125
▁to 0.159423828125
▁show 1.4990234375
▁at 6.59375
▁a 4.546875
▁minimum 1.9794921875
▁an 2.87890625
▁extension 2.80078125
▁of 0.69873046875
▁surv 0.564453125
ival 0.00038361549377441406
▁by 2.625
▁several 3.587890625
▁months 0.032867431640625
▁compared 3.060546875
▁to 0.3193359375
▁chem 2.103515625
other 0.037933349609375
apy 0.005252838134765625
▁alone 0.041717529296875
. 0.375732421875
▁If 3.513671875
▁the 0.446044921875
▁trial 1.3505859375
▁shows 2.130859375
▁more 4.50390625
▁substantial 3.57421875
▁benefits 1.94921875
, 0.390625
▁it 1.9677734375
▁could 0.49365234375
▁position 6.296875
▁Mar 0.239990234375
im 0.002849578857421875
ast 0.0036487579345703125
at 0.0003333091735839844
▁as 0.5390625
▁a 0.3369140625
▁block 4.09765625
b 0.006244659423828125
uster 0.0009684562683105469
▁drug 1.0625
▁with 2.39453125
▁over 5.73046875
▁$ 0.47705078125
1 0.52734375
▁billion 0.164794921875
▁in 0.10205078125
▁annual 0.84521484375
▁sales 0.1785888671875
. 0.416259765625
▁▁▁▁ 11.3125
<0x0A> 0.0648193359375
<0x0A> 0.1702880859375
B 4.1171875
rit 0.11151123046875
ish 0.0090484619140625
▁Bi 0.1968994140625
ote 0.0007123947143554688
ch 0.0192718505859375
' 1.251953125
s 0.003269195556640625
▁share 4.078125
▁price 0.07977294921875
▁has 1.3525390625
▁already 3.689453125
▁ris 1.181640625
en 2.9921531677246094e-05
▁over 2.953125
▁ 0.03839111328125
3 2.103515625
0 0.346435546875
% 0.41064453125
▁in 1.478515625
▁the 0.467041015625
▁past 0.6982421875
▁month 1.4599609375
▁in 3.423828125
▁anticip 0.250732421875
ation 0.0003669261932373047
▁of 0.01763916015625
▁positive 3.00390625
▁trial 1.4873046875
▁results 0.35791015625
. 0.841796875
▁The 1.5107421875
▁company 1.318359375
' 1.1416015625
s 0.0008225440979003906
▁future 5.16015625
▁h 4.71484375
ing 0.00983428955078125
es 0.000881195068359375
▁on 0.06427001953125
▁the 0.9404296875
▁success 0.7978515625
▁of 0.033782958984375
▁Mar 2.986328125
im 0.0009245872497558594
ast 0.0028076171875
at 0.0007171630859375
, 1.763671875
▁as 2.57421875
▁it 2.0859375
▁represents 4.49609375
▁British 3.501953125
▁Bi 0.017578125
ote 0.00015807151794433594
ch 0.005825042724609375
' 0.005767822265625
s 0.00092315673828125
▁most 3.435546875
▁advanced 1.5390625
▁candidate 4.875
▁and 2.45703125
▁the 1.642578125
▁company 2.76953125
' 0.348388671875
s 0.0009188652038574219
▁only 0.57275390625
▁drug 1.896484375
▁in 1.1484375
▁late 4.10546875
- 0.3271484375
stage 0.021575927734375
▁clin 0.83154296875
ical 0.00010442733764648438
▁tri 0.6640625
als 6.413459777832031e-05
. 0.054290771484375
▁While 5.59765625
▁anal 2.552734375
yst 0.00032711029052734375
s 0.031951904296875
▁remain 2.294921875
▁c 1.4375
aut 0.0005702972412109375
iously 0.54931640625
▁optim 0.0501708984375
istic 0.0001556873321533203
, 0.84814453125
▁disappoint 7.78125
ing 0.352294921875
▁trial 0.7119140625
▁results 0.136962890625
▁would 2.3359375
▁be 2.33984375
▁a 0.51123046875
▁major 1.12890625
▁set 0.4892578125
back 0.0147247314453125
▁for 0.2333984375
▁the 0.61083984375
▁company 0.2088623046875
. 1.18359375
<0x0A> 0.99462890625
<0x0A> 0.041595458984375
Mar 3.990234375
im 0.016326904296875
ast 0.00702667236328125
at 0.00084686279296875
' 3.05859375
s 0.0052642822265625
▁mechanism 6.90234375
▁of 0.016204833984375
▁action 0.001651763916015625
▁as 5.5546875
▁an 0.428955078125
▁anti 0.150634765625
- 0.005008697509765625
met 7.46875
ast 0.05072021484375
atic 0.11181640625
▁agent 1.18359375
▁sets 10.8984375
▁it 0.0975341796875
▁apart 0.00897979736328125
▁from 0.038909912109375
▁most 3.205078125
▁other 0.58447265625
▁cancer 2.099609375
▁dru 0.61572265625
gs 4.220008850097656e-05
▁that 3.84375
▁work 2.5546875
▁by 0.2666015625
▁directly 3.01171875
▁attack 3.552734375
ing 0.0016536712646484375
▁tum 1.01171875
or 0.26025390625
▁cells 0.05242919921875
. 0.330078125
▁If 7.375
▁shown 5.46484375
▁effective 2.46484375
▁in 0.55126953125
▁st 8.3046875
om 0.0044097900390625
ach 5.817413330078125e-05
▁cancer 0.06414794921875
, 1.482421875
▁British 4.12890625
▁Bi 0.0076904296875
ote 6.389617919921875e-05
ch 0.0018405914306640625
▁plans 6.7890625
▁to 0.02227783203125
▁test 5.421875
▁Mar 0.52099609375
im 0.0006146430969238281
ast 0.0012340545654296875
at 0.0005407333374023438
▁in 0.255126953125
▁additional 3.208984375
▁cancer 2.375
▁types 1.2060546875
▁including 2.43359375
▁col 3.330078125
ore 0.002841949462890625
ct 9.489059448242188e-05
al 0.0010633468627929688
, 0.392822265625
▁breast 1.1923828125
▁and 1.20703125
▁lung 1.0439453125
▁can 1.0419921875
cers 3.0040740966796875e-05
. 0.1553955078125
▁The 1.990234375
▁company 0.87451171875
▁may 4.76953125
▁also 0.29052734375
▁explore 1.4638671875
▁combinations 4.80859375
▁with 1.0234375
▁other 0.3046875
▁ther 3.462890625
ap 0.00943756103515625
ies 6.0558319091796875e-05
▁like 5.3671875
▁chem 2.875
other 0.031982421875
apy 0.08258056640625
, 1.2607421875
▁target 1.6640625
ed 0.006221771240234375
▁dru 2.86328125
gs 3.6835670471191406e-05
▁and 0.71142578125
▁imm 0.442626953125
un 0.048370361328125
other 0.006317138671875
apy 0.92822265625
. 0.6611328125
<0x0A> 0.9013671875
<0x0A> 0.0210723876953125
The 3.3984375
▁medical 7.05078125
▁community 1.5283203125
▁is 0.94287109375
▁eager 1.5126953125
▁to 2.3359375
▁see 0.78173828125
▁new 3.228515625
▁treatment 4.87890625
▁options 0.67138671875
▁emer 3.154296875
ge 0.0153961181640625
▁for 1.318359375
▁st 1.9072265625
om 0.0006308555603027344
ach 2.5510787963867188e-05
▁cancer 0.0859375
, 1.404296875
▁which 1.08984375
▁is 0.82666015625
▁a 3.087890625
▁dead 1.880859375
ly 0.00383758544921875
▁disease 0.25830078125
▁with 1.0576171875
▁few 3.294921875
▁effective 0.93505859375
▁treat 1.318359375
ments 4.8279762268066406e-05
. 0.298095703125
▁Pos 7.8671875
itive 0.00978851318359375
▁late 8.1640625
- 0.1346435546875
stage 0.2017822265625
▁trial 1.0908203125
▁results 0.262939453125
▁would 1.68359375
▁put 4.48828125
▁British 0.6982421875
▁Bi 0.006626129150390625
ote 6.127357482910156e-05
ch 0.0015048980712890625
▁in 1.361328125
▁a 0.249755859375
▁strong 0.72119140625
▁position 0.03375244140625
▁to 0.50390625
▁gain 2.666015625
▁regul 3.267578125
atory 0.0003991127014160156
▁appro 0.0145111083984375
val 2.384185791015625e-06
▁and 1.505859375
▁market 2.72265625
▁Mar 8.328125
im 0.0005116462707519531
ast 0.0004901885986328125
at 0.0001232624053955078
▁as 0.8955078125
▁early 8.75
▁as 0.1551513671875
▁next 0.65966796875
▁year 0.013031005859375
, 3.22265625
▁bringing 6.44140625
▁hope 1.8740234375
▁to 0.1685791015625
▁patients 0.48486328125
▁and 1.0546875
▁profession 9.453125
als 7.76052474975586e-05
▁fighting 4.78515625
▁this 1.4560546875
▁difficult 3.45703125
▁cancer 1.9248046875
. 0.0611572265625
